@article {Bezerra2022.08.02.22278277, author = {Matheus Filgueira Bezerra and Lilian Caroliny Amorim Silva and R{\^o}mulo Pessoa-e-Silva and Gisele Lino Soares and Filipe Zimmer Dezordi and Gustavo Barbosa de Lima and Raul Em{\'\i}dio de Lima and Tulio L. Campos and Cassia Docena and Anderson Bruno de Oliveira and Maira Galdino da Rocha Pitta and Francisco de Assis da Silva Santos and Michelly Pereira and Gabriel Luz Wallau and Marcelo Henrique Santos Paiva}, title = {Real-life evaluation of a rapid antigen test (DPP{\textregistered} SARS-CoV-2 Antigen) for COVID-19 diagnosis of primary healthcare patients, in the context of the Omicron-dominant wave in Brazil}, elocation-id = {2022.08.02.22278277}, year = {2022}, doi = {10.1101/2022.08.02.22278277}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Rapid antigen tests play an important role in the monitoring and mitigation of the COVID-19 pandemic, as it provides an easy, fast and efficient diagnosis with minimum infrastructure requirements. However, as new variants of concern continue to emerge, mutations in the virus genome may impair the recognition of the mutated antigen by the tests. Therefore, it is essential to re-assess the test{\textquoteright}s sensitivity as the virus mutation profile undergoes significant changes. Here, we prospectively accessed the performance of the DPP{\textregistered} SARS-CoV-2 Antigen test in the context of an omicron-dominant real-life setting. We evaluated 347 unselected individuals (all-comers) from a public testing center in Brazil, performing the rapid antigen test diagnosis at point-of-care with fresh samples. The combinatory result from two distinct RT-qPCR methods was employed as reference and 13 samples with discordant PCR results were excluded. The assessment of the rapid test in 67 PCR-positive and 265 negative samples revealed an overall sensitivity of 80.5\%, specificity of 99.2\% and positive/negative predictive values higher than 95\%. However, we observed that the sensitivity was dependent on the viral load (sensitivity in Ct\<31 = 93.7\%; Ct\>31 = 47.4\%). Furthermore, we were able to confirm that the positive samples evaluated in the study were Omicron (BA.1/BA.1.1) by whole-genome sequencing (n=40) and multiplex RT-qPCR (n=17). Altogether, the data obtained from a real-life prospective cohort supports that the rapid antigen test sensitivity for the Omicron remains high and underscores the reliability of the test for COVID-19 diagnosis in a setting with high disease prevalence and limited PCR testing capability.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe National Council for Scientific and Technological Development funded the productivity research fellowship level 2 for Wallau GL (303902/2019-1). The molecular diagnosis of COVID-19 and characterizations of SARS-CoV-2 variants by real-time PCR at NUPIT SG was carried out through the resources provided by the Caruaru City Administration (13/21 FADE/UFPE/PREFEITURA DE CARUARU and FADE/UFPE/PREFEITURA DE CARUARU PROCESSO: 23076.067808/2021-26), the Brazilian Public Labour Prosecution Office (Ministerio Publico do Trabalho MPT), the Ministry of Science, Technology and Innovation (Ministerio da Ciencia, Tecnologia e Inovacoes MCTI, process 01.20.0026.01) and the Brazilian Ministry of Education (Ministerio da Educacao MEC, process 23076.018503/2020-36).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Centro de Ciencias da Saude - Universidade Federal de Pernambuco gave ethical approval for this work (protocol number 31093420.4.0000.5208).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors}, URL = {https://www.medrxiv.org/content/early/2022/08/03/2022.08.02.22278277}, eprint = {https://www.medrxiv.org/content/early/2022/08/03/2022.08.02.22278277.full.pdf}, journal = {medRxiv} }